|
||
J. Exp. Med.,
Volume 188, Number 10, November 16, 1998 1929-1939
By

From the * Mucosal Immunity Section, National Institutes of Health, Bethesda, Maryland 20892;
and the In this study we describe oxazolone colitis, a new form of experimental colitis. This model is
induced in SJL/J mice by the rectal instillation of the haptenating agent, oxazolone, and is characterized by a rapidly developing colitis confined to the distal half of the colon; it consists
of a mixed neutrophil/lymphocyte infiltration limited to the superficial layer of the mucosa
which is associated with ulceration. Oxazolone colitis is a T helper cell type 2 (Th2)-mediated
process since stimulated T cells from lesional tissue produce markedly increased amounts of interleukin (IL)-4 and IL-5; in addition, anti-IL-4 administration leads to a striking amelioration
of disease, whereas anti-IL-12 administration either has no effect or exacerbates disease. Finally, this proinflammatory Th2 cytokine response is counterbalanced by a massive transforming growth factor-
Laboratorio Di Immunologia, Istituto Superiore Di Sanita, Roma, Italy 00161
(TGF-
) response which limits both the extent and duration of disease: lesional (distal) T cells manifest a 20-30-fold increase in TGF-
production, whereas nonlesional
(proximal) T cells manifest an even greater 40-50-fold increase. In addition, anti-TGF-
administration leads to more severe inflammation which now involves the entire colon. The histologic features and distribution of oxazolone colitis have characteristics that resemble ulcerative colitis (UC) and thus sharply distinguish this model from most other models, which
usually resemble Crohn's disease. This feature of oxazolone colitis as well as its cytokine profile
have important implications to the pathogenesis and treatment of UC.
This article has been cited by other articles:
| TABLE OF CONTENTS |
|